C-Abl Is Required for the Development of Hyperoxia-Induced Retinopathy by Nunes, Irene et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2001/06/1383/09 $5.00
Volume 193, Number 12, June 18, 2001 1383–1391
http://www.jem.org/cgi/content/full/193/12/1383
 
1383
 
c-Abl Is Required for the Development of
Hyperoxia-induced Retinopathy
 
By Irene Nunes,
 
*
 
 Rosemary D. Higgins,
 
‡ 
 
Lucia Zanetta,
 
§
 
Peter Shamamian,
 
§
 
 and Stephen P. Goff
 
*
 
 
 
From the 
 
*
 
Department of Biochemistry and Molecular Biophysics, College of Physicians and Surgeons, 
 
Columbia University, New York, New York 10032; the 
 
‡
 
Department of Pediatrics, Georgetown 
University, Washington, DC 20007; the 
 
§
 
Department of Surgery, New York University School of 
 
Medicine, New York, New York 10016; and the 
 
 
 
Howard Hughes Medical Institute, New York, 
New York 10032
 
Abstract
 
The requirement for the nonreceptor tyrosine kinase c-abl in the pathogenesis of retinopathy of
 
prematurity (ROP) was examined using the mouse model for ROP and 
 
c-abl–
 
deficient mice.
Hyperoxia-induced retinal neovascularization was observed in wild-type and heterozygous
mice but animals that were homozygous null for 
 
c-abl
 
 did not develop a vasoproliferative retin-
 
opathy in response to hyperoxia. Two gene products, endothelin-1 (ET-1) and vascular en-
dothelial growth factor (VEGF), have been implicated in the pathogenesis of ROP. The
mRNA expression of ET-1 and VEGF was assessed in mice maintained in normoxia and in hy-
peroxia-exposed mice. ET-1 mRNA levels were unchanged in wild-type mice throughout the
hyperoxia treatment, suggesting that ET-1 mRNA expression is not regulated by the increase
in inspired oxygen. In wild-type mice maintained in room air, VEGF mRNA levels rose three-
fold from postnatal day 6 (P6) to P17. When wild-type mice were treated with the hyperoxia
regimen, a fivefold decrease in VEGF mRNA expression was observed from P7 to P16. How-
ever, retinal VEGF expression in hyperoxia-treated homozygous null mice did not decrease
 
and remained at control levels. These data suggest that c-abl is required for the hyperoxia-
induced retinal neovascularization and hyperoxia-induced decrease in VEGF mRNA levels.
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Introduction
 
Retinopathy of prematurity (ROP)
 
1 
 
is a vasoproliferative
retinopathy of premature infants that results in severe visual
impairment and blindness (1, 2). Animal models that repli-
cate clinical manifestations of ROP have been used to
characterize the roles of vascular endothelial growth factor
(VEGF [3–6]), VEGF receptors (flk-1 and flt-1 [7]), and
hypoxia inducible factor-1 (HIF-1 [8]) in the pathogenesis
of ROP. Exposure to hyperoxia results in the downregula-
tion of VEGF production, vasoconstriction, cessation of
retinal blood vessel growth, and loss of capillary beds (9).
The vasoconstrictive response to hyperoxia has been pro-
posed to be endothelin-1 (ET-1) dependent (10–13). The
expression of ET mRNA in response to hyperoxia is un-
known. The drop in retinal vessel density occurs via apop-
tosis and has been attributed to decreased levels of VEGF
mRNA, as VEGF is required for the viability of vascular
endothelial cells (4, 5). The resulting nonperfused retinal
tissue responds by increasing its VEGF production and new
blood vessel growth (14, 15). VEGF-induced angiogenesis
is Src dependent and Src kinase activity protects newly
formed vessels from apoptosis (16).
The mechanism by which oxygen levels elicit changes
in VEGF expression is poorly understood. However, reac-
tive oxygen intermediates have been implicated in the
pathogenesis of ROP (17). The administration of antioxi-
dants to mice exposed to a hyperoxia regimen prevented
the development of retinopathy (18). In addition, there is
evidence that HIF-1 binds to DNA damaged by oxidation
and may affect the repair rate of oxidation-induced strand
breaks (19).
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 ET-1, endothelin-1; P, postnatal; PAS,
periodic acid-schiff; ROP, retinopathy of prematurity; VEGF; vascular
endothelial growth factor; wt, wild-type. 
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c-Abl is a protooncogenic nonreceptor tyrosine kinase
with an NH
 
2
 
-terminal domain that is homologous to Src
family members and a unique COOH-terminal region (20).
Mutant forms of c-abl have been characterized in leukemias
of mice and humans (21). There are two isoforms of c-abl
that differ at the NH
 
2
 
-terminal sequences due to alternate
5
 
 
 
 exons (20, 22, 23). The c-abl protein is ubiquitously ex-
pressed and localizes to the cytoplasm and nucleus where it
has distinct roles (20, 23). Effects of c-abl on the cell cycle,
apoptosis, and cellular transformation depend on protein in-
teractions with its various functional domains: Src homol-
ogy (SH)3, SH2, tyrosine kinase domain, proline-rich bind-
ing sites, and actin binding domain. c-Abl participates in the
signal transduction pathways induced by growth factors
(24), integrins (25), and genotoxic stresses such as ionizing
radiation and hydrogen peroxide (26–29). c-Abl tyrosine
kinase activity may be enhanced by Src kinases that directly
phosphorylate the kinase domain of c-abl (24). Both VEGF
and ET-1 receptor signaling require c-Src–dependent path-
ways (16, 30), and these cytokines have been implicated in
the pathogenesis of oxygen-induced neovascularization.
Because c-abl participates in the cellular response to oxida-
tion-induced DNA damage and in Src kinase–dependent
signaling pathways, we hypothesized that c-abl may be in-
volved in the angiogenic response to hyperoxia.
The in vivo requirement of c-abl for hyperoxia-induced
neovascularization was investigated using an established
mouse model for ROP and mice carrying knockout muta-
tions of the 
 
c-abl
 
 gene (9, 31). We report that, unlike wild-
type (wt) control animals, mice homozygous for a 
 
c-abl
 
 null
mutation do not develop neovascular retinopathy in re-
sponse to hyperoxia. To determine if retinal VEGF and
ET-1 expression in response to hyperoxia are aberrantly
regulated, their mRNA levels were analyzed using RNase
protection assays. We observe that ET-1 mRNA levels in
retinas of wt and homozygous 
 
c-abl
 
 null animals do not dif-
fer, and exposure to the hyperoxia regimen does not alter
ET-1 mRNA levels in either wt or 
 
c-abl
 
 null animals. As re-
ported by others, we find that retinal VEGF mRNA levels
in wt animals change in response to hyperoxia. However,
VEGF mRNA levels remained unchanged in oxygen-
exposed 
 
c-abl
 
 null mice compared with control animals.
 
Materials and Methods
 
Mice.
 
All mice were treated in accordance with the Associa-
tion for Research in Vision and Ophthalmology Statement for
the Use of Animals in Ophthalmic and Vision Research. 
 
c-Abl
 
null mice were generated (31) and genotyped by PCR (32) as de-
scribed previously. They were maintained in a 129Sv/Ev 
 
 
 
C57Bl/6J hybrid background. Wt C57Bl/6 mice were purchased
from Taconic Laboratories.
 
Mouse Model of ROP.
 
Oxygen-induced retinopathy was elic-
ited in mice according to a previously established model (9, 33).
In brief, postnatal day 7 (P7) mice were exposed to 75% oxygen
with their nursing mother for 5 d in an infant incubator (Oh-
meda). On P12, animals were returned to normoxia and killed
between P16 and P20 by lethal intraperitoneal injection of so-
 
dium pentobarbital. The greatest neovascular response occurs af-
ter P17 in this model (9). Age-matched animals were maintained
in normoxia for the duration of the experiment.
To study the retinal vascular pattern, fluorescein angiography
was performed as described previously (9). Animals were given a
lethal dose of sodium pentobarbital and a median sternotomy was
performed. The left ventricle was perfused with fluorescein-con-
jugated dextran (34). Eyes were enucleated and placed in 4%
paraformaldehyde PBS for 4 to 24 h. Retinas were dissected and
flat mounted. Retinal whole-mounts were visualized using fluo-
rescent microscopy. Two independent observers scored the vaso-
proliferative response in a masked fashion using the retinopathy
scoring system (33). Data were subject to analysis of variance us-
ing the Mann-Whitney test to test for differences among the total
retinopathy scores of individual groups.
To quantify the neovascular response, nuclei of new blood
vessels were periodic acid-Schiff (PAS) stained and counted (9).
Mice were killed on P17–20 and perfused with 4% paraformalde-
hyde in PBS. Frozen tissue sections (8–9-
 
 
 
m thick) from mid-
peripheral retina were prepared and stained with PAS and hema-
toxylin. A minimum of six sections from both eyes per animal
was prepared for analysis. Vascular cell nuclei that were present
beyond the inner limiting membrane into the vitreous were
counted in a masked fashion using light microscopy. The number
of vascular nuclei for each eye was averaged. Student 
 
t 
 
tests were
used to test for differences between hyperoxia and control treat-
ment groups.
 
Corneal Angiogenesis Assay.
 
Hydron pellets containing 250 ng
VEGF (121 kD; R&D Systems) and sucralfate were prepared and
surgically implanted into the mouse corneal stroma adjacent to
the temporal limbus (35). Sham pellets were prepared using PBS
instead of VEGF. 3-wk-old male and female mice that were
 
 
 
/
 
 
 
 or 
 
 
 
/
 
 
 
 for 
 
c-abl
 
 were used for pellet implantation. On day
7 after implantation, corneas were evaluated and photographed
using slit lamp biomicroscopy.
 
RNase Protection Assay for ET-1 and VEGF.
 
The ET-1 cDNA
fragment used to generate the ET-1 riboprobe contains 502 bp of
the 5
 
 
 
 coding region of the preproendothelin-1 cDNA (residues
426 to 928; reference 36). The fragment was obtained by PCR
amplification of the Marathon mouse liver cDNA library
(CLONTECH Laboratories, Inc.) using the Expanded High Fi-
delity PCR system (Boehringer) and synthetic oligonucleotide
primers: 5
 
 
 
 primer, 5
 
 
 
-AATTTCTGCCAAGCAGGAAAA-
GAAC; 3
 
 
 
 primer, 5
 
 
 
-TCCTTCGAGTATGTTTTCAATT-
TGT. The PCR product was digested with ApaI and XbaI and
cloned into similarly digested pBluescript KS
 
 
 
 vector DNA
(Stratagene). The VEGF cDNA fragment used to generate the
VEGF riboprobe contains 411 bp of the 5
 
 
 
 coding region that is
common to murine VEGF-1, -2, and –3 cDNAs (residues 7–418;
reference 37). The fragment was obtained by PCR amplification
of the Marathon mouse liver cDNA library using the Expanded
High Fidelity PCR system and synthetic oligonucleotide primers:
5
 
 
 
 primer, 5
 
 
 
 ATATGGATCCATGAACTTTCTGCTGTCT-
TGGGTG; 3
 
 
 
 primer, 5
 
 
 
 ATGAATTCTCCTGTCTTTCT-
TTGGTCTGCATTC. The PCR product was TA cloned into
pCRII-TOP0 (Invitrogen) followed by subcloning the Not1 and
HindIII insert fragment into digested pBluescript KS
 
 
 
.
Single-stranded antisense [
 
32
 
P]RNA probes were prepared
from ET-1 and VEGF cDNA cloned fragments using the
pBluescript plasmids described above as templates for transcrip-
tion by T7 and T3 polymerases, respectively. A mouse actin ri-
boprobe (304 nt) was prepared in parallel using pTRI-
 
 
 
-actin
as a template (Ambion) and T7 polymerase. The full-length 
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ET-1 and VEGF riboprobes are 584 and 615 nt, respectively.
Transcription reactions proceeded according to instructions
provided in the MAXIscript transcription kits (Ambion). For
RNase Protection assays, ET-1, VEGF, and actin riboprobes
(200 pg) were coprecipitated with total RNA (3–5 
 
 
 
g) at a
100-fold molar excess of probe to target mRNAs and hybrid-
ized in 80% formamide hybridization buffer (RPAIII; Ambion)
overnight at 42
 
 
 
C. Total RNA was isolated from dissected reti-
nas using RNAzol B (Tel-test). Unhybridized probes were di-
gested with an RNase A/RNase T1 mix (RPAIII; Ambion) and
protected probes were precipitated with yeast carrier RNA (10
 
 
 
g). Digestion of the polylinker sequence present in protected
riboprobes generates shortened fragments: actin, 250 bp; ET-1,
484 bp; VEGF, 410 bp. Precipitated RNA fragments were re-
solved on a 7 M urea-5% polyacrylamide gel. Bands were visu-
alized and quantitated by PhosphorImager analysis (Molecular
Dynamics).
 
Results
 
c-Abl–deficient Mice Do Not Develop Retinal Neovasculariza-
tion in Response to Hyperoxia.
 
To determine if mice defi-
cient in c-abl are susceptible to hyperoxia-induced neovas-
cularization, a mouse model for ROP was employed (9).
Matings of mice that were heterozygous for the 
 
c-abl
 
 null
allele were established to generate control and experimental
age-matched litters (31). Control animals were maintained
in room air (normoxia) for the duration of the experiment,
and the experimental group was exposed to a hyperoxia
regimen (5, 9, 14). In this regimen, pups and their nursing
mother were exposed to hyperoxia (75% oxygen) starting
on P7 for 5 d followed by their return to normoxia on P12
for an additional 4–5 d. Retinas were harvested for exami-
nation of its vasculature by fluorescein angiography on
Figure 1. Flat-mounted reti-
nas perfused with fluorescein-
dextran from wt and c-abl
homozygous null mice.  Age-
matched wt and c-abl /  mice
were either maintained in nor-
moxia or exposed to 75% oxygen
from P7 to P12 and then placed
in room air from P12 to P20.
The retinal vasculature of all ani-
mals was examined by fluores-
cein angiography on P17–20. 
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P17–20. Animals that were wt (Fig. 1) or heterozygous
(data not shown) for 
 
c-abl
 
 developed a strong vasoprolifera-
tive response to the hyperoxia treatment when compared
with wt or 
 
c-abl
 
 heterozygous animals kept in normoxia.
However, retinas of 
 
c-abl 
 
homozygous null mice exposed
to hyperoxia exhibit minimal to no retinopathy when
compared with retinas prepared from all mice maintained
in normoxia (Fig. 1). This suggested that c-abl is required
for hyperoxia-induced retinopathy to develop.
A retinopathy scoring system was used to quantify the
extent of vasoproliferation present in each retinal whole-
mount (33). Two independent observers that were blinded
to specimen identity examined each section. They assigned
a numerical score from 0 to 4, where 4 corresponds to the
maximal response, for each of the following categories:
blood vessel growth, blood vessel tufts, extra retinal
 
neovascularization, central vasoconstriction, retinal hemor-
rhage, and tortuosity of vessels. The scores for all six cate-
gories were totaled. When the code was broken, the total
scores were tabulated and used to quantify the severity of
the neovascular retinopathy developed by wt, 
 
 
 
/
 
 
 
, and
 
 
 
/
 
 
 
 mice. Retinas of wt or 
 
 
 
/
 
  
 
mice exposed to hyper-
oxia exhibited predominantly vessel tufts, central vasocon-
striction, and vessel tortuosity. Retinal hemorrhages and
extra retinal vessels were minor aspects of the retinopathy.
A scatter distribution of the total retinopathy scores ob-
tained from wt, heterozygous, and homozygous 
 
c-abl
 
 null
mice exposed to normoxia or hyperoxia was generated
(Fig. 2). The median total scores for all the animals main-
tained in room air were zero. Upon exposure to hyperoxia,
the wt showed an increase in the median score to 3.5,
whereas the heterozygotes showed an increase to 2. The
neovascular retinopathy developed in response to hyper-
oxia demonstrated a wide spread of total retinopathy
scores. Nonparametric analysis of variance (Mann-Whitney
test) revealed no significant difference between wt and het-
erozygote mice and a significant difference (
 
P
 
 
 
 
 
 0.0001)
between the normoxia and hyperoxia-exposed groups. In
contrast, the median scores observed for homozygous null
mice maintained in room air and exposed to hyperoxia
were both zero. The median values observed for the ho-
mozygous animals showed a highly significant difference
(
 
P 
 
 
 
 0.0001) from those of hyperoxia-exposed control
(
 
 
 
/
 
 
 
 and 
 
 
 
/
 
 
 
) mice. These data demonstrate that, taken
together, control animals (
 
 
 
/
 
 
 
 and 
 
 
 
/
 
 
 
) developed a
moderate retinal neovascular response to hyperoxia as de-
scribed previously, whereas homozygous 
 
c-abl
 
 null animals
did not develop a retinopathy (9).
To confirm the data obtained using the subjective retinal
scoring system, the nuclei of new blood vessels that extend
beyond the inner limiting membrane into the vitreous
were counted (9). The nuclei were observed in PAS-
stained retinal frozen sections (Fig. 3 A). Averaged numbers
of nuclei from retinas of mice exposed to normoxia and
hyperoxia were determined (Fig. 3 B). The mean numbers
of nuclei observed for wt and heterozygotes exposed to hy-
peroxia were 20 and 17, respectively, whereas negligible
numbers (
 
 
 
5) of neovascular nuclei were observed in reti-
nas of mice (wt, 
 
 
 
/
 
 
 
, and 
 
 
 
/
 
 
 
) maintained in room air.
The difference in the average numbers of nuclei between
normoxia and hyperoxia-treated groups was significant
(
 
P 
 
 
 
 0.001). In contrast, the mean number of nuclei
counted in retinas of homozygous 
 
c-abl
 
 null mice exposed
to hyperoxia was 5.5 as observed in normoxia control reti-
nas. There is a significant difference (
 
P 
 
 
 
 0.002) in the
means between homozygous (
 
 
 
/
 
 
 
) and control (
 
 
 
/
 
 
 
 and
 
 
 
/
 
 
 
) mice exposed to hyperoxia. The nuclei count data
confirm the total retinopathy scoring values, demonstrating
that the 
 
c-abl
 
–deficient mice failed to develop hyperoxia-
induced vasoproliferative retinopathy.
 
ET-1 mRNA Expression in wt Mice Is Constant throughout
the Hyperoxia Regimen.
 
Constriction of retinal vessels is
characteristic of the retinopathy and has been proposed to
be ET-1 mediated (13). However, there are no reports that
Figure 2. Scatter distribution of total retinopathy scores for normoxia
and hyperoxia-exposed wt and c-abl–deficient mice. The vasculature of
flat-mounted P17 retinas from mice exposed to (A) room air or the hy-
peroxia regimen (B) was assessed using the total retinopathy scoring sys-
tem. The number of retinas observed for each total retinopathy score is
plotted. A total score of 0 indicates normal retinal vasculature and a total
score of 17 reflects severe retinopathy. Arrows point to the median total
score for each group of mice. 
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describe retinal ET-1 mRNA expression in response to ox-
ygen or in the murine ROP model we employed. To de-
termine if ET-1 mRNA expression is differentially regu-
lated in wt mice by oxygen, we assessed ET-1 mRNA
levels in retinas of normoxia control and hyperoxia-treated
experimental animals using RNase protection assays. Reti-
nas from P6 and P17 control (normoxia) mice and from P7
to P16 experimental mice, i.e., mice exposed to the hyper-
oxia regimen, were used (Fig. 4). ET-1 was found to be
expressed constitutively and levels were unchanged in
the normoxia and hyperoxia-exposed retinas harvested
throughout the hyperoxia regimen. These data suggest that
retinal ET-1 mRNA levels are refractory to changes in in-
spired oxygen tension.
 
Mice Deficient in c-abl Develop a Normal VEGF-induced An-
giogenic Response.
 
Because VEGF is involved in the devel-
opment of hyperoxia-induced retinal vasoproliferation (5)
 
and mice deficient in c-abl failed to develop hyperoxia-
induced retinopathy, we sought to determine if mice that
lack c-abl could respond normally to VEGF. To examine if
homozygous 
 
c-abl null mice generate an angiogenic re-
sponse to exogenously supplied VEGF, a corneal angiogen-
esis assay was employed (35). A PBS sham or VEGF-satu-
rated Hydron pellet was implanted surgically in corneas of
3-wk-old wt and homozygous null mice. New blood ves-
sels emerged from the limbal vasculature of wt and c-abl / 
mice toward the VEGF-saturated pellet, whereas no vessels
were observed in animals with sham pellets (Fig. 5). The
density of angiogenic vessels emerging from the limbus to-
ward the pellet was similar between  /  and  /  mice.
These observations demonstrate that c-abl activity is not
required for VEGF-induced signal transduction and that
the c-abl /  mice responded normally to the ectopic admin-
istration of VEGF.
Figure 3. (A) Representative PAS-
stained sections. Retinal sections from
 / ,  / , and  /  c-abl mice (P17)
were compared between normoxia con-
trol and experimental animals exposed to
the hyperoxia regimen. Arrows point to
new blood vessels grown beyond the in-
ner limiting membrane. (B) Numbers of
extra retinal neovascular nuclei in PAS-
stained retinal sections. P17–P20 retinas
from wt and c-abl–deficient mice exposed
to room air or the hyperoxia were sec-
tioned and stained with PAS as shown in
panel A. The total number of vascular
nuclei extending outside the inner limit-
ing membrane in 6- m retinal cross-sec-
tions was counted. The average number
of nuclei for number (n) of examined
eyes and standard error bars are graphed.1388 c-Abl Is Required for the Development of Hyperoxia-induced Retinopathy
VEGF mRNA Expression in wt Mice Is Regulated Differen-
tially in Response to Hyperoxia. To better understand the
effect of the hyperoxia treatment on VEGF mRNA ex-
pression, we first characterized VEGF mRNA levels in
two wt mouse strains using RNase Protection assays. The
C57Bl/6 strain used traditionally in the mouse ROP
model and the hybrid 129Sv/Ev   C57Bl/6 strain in
which the c-abl null allele is propagated were examined.
Total RNA (5  g) was hybridized to a VEGF riboprobe
that recognizes all three isoforms of murine VEGF.
mRNA levels were assayed in retinas of normoxia control
(P6 and P17) animals and experimental animals (P7 to P17)
exposed to the hyperoxia regimen. Levels for C57Bl/6
normoxia control mice increased threefold in P17 retinas
compared with P6 retinas (Fig. 6, lanes 1 and 2) suggesting
that VEGF expression is regulated throughout retinal vas-
cular development (4, 38). VEGF expression remained
constant when C57Bl/6 mice were exposed to hyperoxia
(P7 to P12, lanes 3 to 6) but rose sixfold when mice were
returned to room air (P14 to P17, lanes 7 to 9; Fig. 6).
These results are consistent with those previously pub-
lished for C57Bl/6 mice (5, 14, 39).
Next, VEGF mRNA levels were determined for the wt
hybrid strain. Expression levels in normoxia control P6 and
P17 mice were similar to those seen for C57Bl/6. mRNA
levels in retina of hyperoxia-treated mice were relatively
constant from P7 to P12 (Fig. 4, lanes 3 to 6), but a signifi-
cant four- to fivefold decrease in expression was observed
by P16 (lane 8) when compared with levels in P7–12 reti-
nas. The decrease in expression occurred when the animals
were returned to normoxia. These results are distinct from
those seen by others and us for C57Bl/6 and suggest that
the kinetics of VEGF mRNA induction in response to hy-
peroxia differ among mouse strains.
Exposure to Hyperoxia Does Not Elicit Decreased VEGF
mRNA Expression in Retinas of c-abl–deficient Mice. Be-
cause the homozygous null mice were protected from hy-
peroxia-induced retinal stress (Figs. 1–3), we sought to de-
termine if differences in retinal VEGF mRNA expression
among wt, heterozygous, and homozygous c-abl mice
could be involved. Mice used for these experiments were
of the hybrid strain. VEGF mRNA levels were assessed in
P17 retinas of mice maintained in room air and of mice ex-
posed to the hyperoxia regimen using RNase protection
assays. VEGF mRNA expression in wt mice exposed to
hyperoxia (Fig. 7, lanes 4 and 7) decreased sevenfold com-
pared with the normoxia control level (Fig. 7, lane 3). In
contrast, the VEGF mRNA levels in retinas of homozy-
gous null animals exposed to the hyperoxia treatment re-
mained consistently unchanged (Fig. 7, lanes 8 and 11)
from levels observed in normoxia control retinas (Fig. 7,
lanes 3 and 5). These data suggest that homozygous animals
lacking any c-abl do not regulate VEGF mRNA expression
in response to oxygen.
The VEGF expression levels in retinas of heterozygotes
exposed to the hyperoxia regimen was variable as seen in
repeat experiments (lanes 7 and 10). The variation in retinal
VEGF expression among hyperoxia-treated heterozygotes
correlates with the wide distribution in their total retinopa-
thy scores (Fig. 2 B). These results suggest that there may
Figure 4. RNase protection assays of retinal VEGF and ET-1 expres-
sion in wt hybrid mice. Total retinal RNA (3–5  g) was prepared from
P6 and P17 wt mice exposed to room air only (control animals) and from
mice throughout the hyperoxia regimen (experimental animals). The hy-
peroxia treatment consisted of a 5-d exposure to 75% oxygen between
P7 to P12 followed by the return to normoxia from P12 to P16. RNAs
were hybridized with VEGF, ET-1, and actin riboprobes (arrows). Ribo-
probes alone were treated with ( ) or without ( ) RNase to verify that
digestions were complete. The protected fragments were resolved by
urea/SDS-PAGE and visualized by PhosphorImager. Band density was
quantified using ImageQuant software. The normoxia and hyperoxia hy-
bridization experiments were performed using riboprobes prepared on
separate occasions. Therefore, the specific activities differed and expres-
sion levels between these two groups should not be directly compared.
Figure 5. Corneal angiogene-
sis assay of wt and c-abl–deficient
mice. VEGF-saturated or PBS
sham Hydron pellets were im-
planted in corneas of 3-wk-old
mice and 7 d postimplantation
corneas were examined using
slit-lamp biomicroscopy.1389 Nunes et al.
be a gene dosage effect for the reduction of VEGF mRNA
levels mediated by one or two copies of c-abl.
Discussion
Our data demonstrate that c-abl is required for the de-
velopment of vasoproliferative retinopathy induced by hy-
peroxia in the murine model of ROP. Oxygen-induced
blood vessel growth, vessel tufts, central vasoconstriction,
and vessel tortuosity were readily detected in retinal flat-
mounts of wt and c-abl heterozygous mice. Retinal hemor-
rhages and extra retinal neovascularization were not pro-
minent features of the retinopathies. Mice that were
homozgyous null for c-abl did not develop the oxygen-
induced retinal vascular obliteration or neovascularization
that was observed in control mice. The specific role for
c-abl in the retinal response to hyperoxia remains un-
known. We speculate that c-abl contributes to the signaling
network responsible for sensing and responding to intracel-
lular oxidative effects.
Vasoconstriction of the central retinal vasculature has
been described in animals treated with hyperoxia (9, 12)
and ET-1 activity has been implicated in retinal vasocon-
striction (10, 11, 13). Because it was unknown if hyperoxia
induces altered ET-1 expression, we assessed retinal ET-1
mRNA levels in wt mice maintained in room air and ex-
posed to the hyperoxia regimen. ET-1 mRNA levels re-
mained constant in P6 and P17 retinas maintained in nor-
moxia and did not change throughout the hyperoxia
regimen. These data indicate that retinal ET-1 expression
levels may not be regulated postnatally during retinal an-
giogenesis or change in response to increased levels of in-
spired oxygen. Nevertheless, a currently undefined role for
constitutively expressed ET-1 may be important for normal
retinal angiogenesis and vascular homeostasis.
To better understand why homozygous c-abl null mice
were refractory to hyperoxia-induced stress as observed by
their failure to develop a neovascular response to hyper-
oxia, we examined if VEGF-dependent signaling was aber-
rant in c-abl–deficient mice. A role for VEGF in oxygen-
induced retinopathy has been documented by others (5, 7,
14, 15, 40, 41). Control and c-abl–deficient animals gener-
ated a robust neovascular response to VEGF-saturated cor-
neal pellets indicating that c-abl is not necessary for VEGF-
dependent signal transduction.
As the in vivo  response to ectopically administered
VEGF was intact in homozygous null mice, we analyzed
VEGF mRNA expression. VEGF mRNA levels have been
documented to be differentially regulated in the mouse
model for ROP (5, 14, 41). Others and we observed a fall
in VEGF mRNA levels when C57Bl/6 mice were exposed
to 75% oxygen, whereas a rise in levels occurred when ani-
mals were returned to normoxia. It has been proposed that
the relative hypoxia experienced when animals are re-
moved from 75% oxygen and placed in normoxia induces
an accumulation of VEGF mRNA (42, 43). Also, we char-
acterized the VEGF mRNA levels in our wt hybrid
(129Sv/Ev   C57Bl/6J) mice throughout the hyperoxia
regimen. The kinetics of VEGF mRNA expression in-
duced by hyperoxia differed between wt C57Bl/5 and wt
hybrid mice. The difference in gene regulation in response
to oxygen among strains suggests that there may be multi-
ple roles for VEGF in the development of oxygen-induced
retinopathy. Recent results from the supplemental thera-
peutic oxygen for prethreshold (STOP)-ROP clinical trial
in which supplemental oxygen therapy is administered to
inhibit retinal neovascularization also raise the possibility
that the role of VEGF in vasoproliferation is complex (2).
Because hyperoxia-induced retinopathy was not ob-
served in c-abl–deficient mice and regulation of VEGF ex-
pression is important to the development of ROP, we de-
termined whether c-abl knockout mice showed abnormal
VEGF mRNA regulation when exposed to the hyperoxia
regimen. Whereas hyperoxia-treated hybrid wt mice
showed a large decrease in VEGF mRNA levels by
P16, retinas of P16 hyperoxia-treated c-abl–deficient mice
Figure 6. RNase protection assays of retinal VEGF expression in wt
C57Bl/6 mice. Total retinal RNA (3–5  g) was prepared from P6 and
P17 wt mice exposed to room air only (control animals) and from mice
throughout the hyperoxia regimen (experimental animals). The hyper-
oxia treatment consisted of a 5-d exposure to 75% oxygen between P7 to
P12 followed by the return to normoxia from P12 to P17. RNAs were
hybridized with VEGF and actin riboprobes.
Figure 7. RNase protection assays of retinal VEGF expression in wt
and c-abl–deficient mice exposed to normoxia or hyperoxia. Total RNA
was prepared from P17 retinas of age-matched mice (hybrid strain)
maintained in room air or exposed to hyperoxia from P7 to P12. Data
from repeat experiments (expt) are presented. RNA was hybridized to
VEGF and actin riboprobes in the same reaction tube. To control for
RNA levels among hybridizations, an actin riboprobe was included in
the reaction. The specific activity of the actin riboprobe was lowered by
addition of cold CTP to the transcription reactions. This was necessary
in order to visualize both the VEGF and the relatively more abundant
actin messages on the same gel. Protected fragments (arrows) were re-
solved by urea/SDS-PAGE and visualized using the PhosphorImager.1390 c-Abl Is Required for the Development of Hyperoxia-induced Retinopathy
showed no such decrease. These data suggest that c-abl is
required for the hyperoxia-induced downregulation of
VEGF mRNA observed in the hybrid strain. Moreover,
this observation implies that c-abl contributes to signal
transduction pathways that regulate VEGF gene expression.
Taken together, our studies suggest that inhibition of
c-abl activity may protect neonates from developing ROP.
The therapeutic use of the c-abl tyrosine kinase inhibitor
STI571 in the treatment of patients with chronic myeloge-
nous leukemia has been shown to be promising (44). Ex-
periments are currently underway to determine if adminis-
tration of STI571 to wt mice can mimic the c-abl null
phenotype and, thus, prevent the development of hyper-
oxia-induced retinopathy.
We thank Dr. Guangxia Gao for invaluable discussions throughout
this project and for technical advice about PCR amplification from
cDNA libraries. We are grateful to Dr. Marianna Orlova for pro-
viding technical advice on RNase protection assays and to Dr. Yun
Yan for technical support.
This work was support by grants from the National Eye Institute
(K08 EY00373 to I. Nunes and K11 EY00330 to R.D. Higgins).
S.P. Goff is an investigator of the Howard Hughes Institute.
Submitted: 5 September 2000
Revised: 13 April 2001
Accepted: 15 May 2001
References
1. Phelps, D.L. 1995. Retinopathy of prematurity. Pediatr. Rev.
16:50–56.
2. Hay, W.W.J., and E.F. Bell. 2000. Oxygen therapy, oxygen
toxicity, and the STOP-ROP trial. Pediatrics. 105:424–425.
3. Benjamin, L.E., I. Hemo, and E. Keshet. 1998. A plasticity
window for blood vessel remodelling is defined by pericyte
coverage of the preformed endothelial network and is regu-
lated by PDGF-B and VEGF. Development. 125:1591–1598.
4. Alon, T., I. Hemo, A. Itin, J. Pe’er, J. Stone, and E. Keshet.
1995. Vascular endothelial growth factor acts as a survival fac-
tor for newly formed retinal vessels and has implications for
retinopathy of prematurity. Nat. Med. 1:1024–1028.
5. Pierce, E.A., E.D. Foley and L.E. Smith. 1996. Regulation of
vascular endothelial growth factor by oxygen in a model of
retinopathy of prematurity [published erratum at 115:427].
Arch. Ophthalmol. 114:1219–1228.
6. Stone, J., A. Itin, T. Alon, J. Pe’er, H. Gnessin, T. Chan-
Ling, and E. Keshet. 1995. Development of retinal vascula-
ture is mediated by hypoxia-induced vascular endothelial
growth factor (VEGF) expression by neuroglia. J. Neurosci.
15:4738–4747.
7. Robbins, S.G., V.S. Rajaratnam and J.S. Penn. 1998. Evi-
dence for upregulation and redistribution of vascular endo-
thelial growth factor (VEGF) receptors flt-1 and flk-1 in the
oxygen-injured rat retina. Growth Factors. 16:1–9.
8. Ozaki, H., A.Y. Yu, N. Della, K. Ozaki, J.D. Luna, H. Ya-
mada, S.F. Hackett, N. Okamoto, D.J. Zack, G.L. Semenza
and P.A. Campochiaro. 1999. Hypoxia inducible factor-
1alpha is increased in ischemic retina: temporal and spatial
correlation with VEGF expression. Invest. Ophthalmol. Vis.
Sci. 40:182–189.
9. Smith, L.E., E. Wesolowski, A. McLellan, S.K. Kostyk, R.
D’Amato, R. Sullivan and P.A. D’Amore. 1994. Oxygen-
induced retinopathy in the mouse. Invest. Ophthalmol. Vis.
Sci. 35:101–111.
10. Brown, S.M., and L.M. Jampol. 1996. New concepts of reg-
ulation of retinal vessel tone. Arch. Ophthalmol. 114:199–204.
11. Murata, M., M. Nakagawa, and S. Takahashi. 1998. Selective
expression of endothelin 1 mRNA in rat retina. Ophthalmo-
logica. 212:331–333.
12. McLeod, D.S., R. Brownstein, and G.A. Lutty. 1996. Vaso-
obliteration in the canine model of oxygen-induced retinop-
athy. Invest. Ophthalmol. Vis. Sci. 37:2099–2109.
13. Takagi, C., G.L. King, H. Takagi, Y.W. Lin, A.C. Clermont
and S.E. Bursell. 1996. Endothelin-1 action via endothelin
receptors is a primary mechanism modulating retinal circula-
tory response to hyperoxia. Invest. Ophthalmol. Vis. Sci. 37:
2099–2109.
14. Pierce, E.A., R.L. Avery, E.D. Foley, L.P. Aiello, and L.E.
Smith. 1995. Vascular endothelial growth factor/vascular
permeability factor expression in a mouse model of retinal
neovascularization. Proc. Natl. Acad. Sci. USA. 92:905–909.
15. Aiello, L.P., E.A. Pierce, E.D. Foley, H. Takagi, H. Chen, L.
Riddle, N. Ferrara, G.L. King, and L.E. Smith. 1995. Sup-
pression of retinal neovascularization in vivo by inhibition of
vascular endothelial growth factor (VEGF) using soluble
VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci.
USA. 92:10457–10461.
16. Eliceiri, B.P., R. Paul, P.L. Schwartzberg, J.D. Hood, J. Leng
and D.A. Cheresh. 1999. Selective requirement for Src ki-
nases during VEGF-induced angiogenesis and vascular per-
meability. Mol. Cell. 4:915–924.
17. Kuroki, M., E.E. Voest, S. Amano, L.V. Beerepoot, S.
Takashima, M. Tolentino, R.Y. Kim, R.M. Rohan, K.A.
Colby, K.T. Yeo and A.P. Adamis. 1996. Reactive oxygen
intermediates increase vascular endothelial growth factor ex-
pression in vitro and in vivo. J. Clin. Invest. 98:1667–1675.
18. Penn, J.S., B.L. Tolman, and L.E. Bullard. 1997. Effect of a
water-soluble vitamin E analog, trolox C, on retinal vascular
development in an animal model of retinopathy of prematu-
rity. Free Radic. Biol. Med. 22:977–984.
19. Rodriguez, H., R. Drouin, G.P. Holmquist, and S.A. Ak-
man. 1997. A hot spot for hydrogen peroxide-induced dam-
age in the human hypoxia-inducible factor I binding site of
the PGK 1 gene. Arch. Biochem. Biophys. 338:207–212.
20. Van Etten, R. 1999. Cycling, stressed-out and nervous: cel-
lular functions of c-Abl. Trends Cell Biol. 9:179–186.
21. Melo, J. V. 1996. The diversity of BCR-ABL fusion proteins
and their relationship to leukemia phenotype. Blood. 88:
2375–2384.
22. Witte, O.N. 1986. Functions of the abl oncogene. Cancer
Surv. 5:183–197.
23. Shaul, Y. 2000. c-abl: activation and nuclear targets. Cell
Death Differ. 7:10–16.
24. Plattner, R., L. Kadlec, K.A. DeMali, A. Kazlauskas, and
A.M. Pendergast. 1999. c-Abl is activated by growth factors
and Src family kinases and has a role in the cellular response
to PDGF. Genes Dev. 13:2400–2411.
25. Lewis, J.M., R. Baskaran, S. Taagepera, M.A. Schwartz, and
J.Y. Wang. 1996. Integrin regulation of c-Abl tyrosine kinase
activity and cytoplasmic-nuclear transport. Proc. Natl. Acad.
Sci. USA. 93:15174–15179.
26. Kharbanda, S., Z.M. Yuan, R. Weichselbaum, and D. Kufe.
1997. Functional role for the c-Abl protein tyrosine kinase in
the cellular response to genotoxic stress. Biochim. Biophys.1391 Nunes et al.
Acta. 1333:1–7.
27. Liu, Z.G., R. Baskaran, E.T. Lea-Chou, L.D. Wood, Y.
Chen, M. Karin, and J.Y. Wang. 1996. Three distinct signal-
ling responses by murine fibroblasts to genotoxic stress. Na-
ture. 384:273–276.
28. Sun, X., P. Majumder, H. Shioya, F. Wu, S. Kumar, R. Weich-
selbaum, S. Kharbanda, and D. Kufe. 2000. Activation of the
cytoplasmic c-Abl tyrosine kinase by reactive oxygen species.
J. Biol. Chem. 275:17237–17240.
29. Sun, X., F. Wu, R. Datta, S. Kharbanda, and D. Kufe. 2000.
Interaction between protein kinase C delta and the c-Abl ty-
rosine kinase in the cellular response to oxidative stress. J.
Biol. Chem. 275:7470–7473.
30. Simonson, M.S., Y. Wang, and W.H. Herman. 1996. Nu-
clear signaling by endothelin-1 requires Src protein-tyrosine
kinases. J. Biol. Chem. 271:77–82.
31. Tybulewicz, V.L., C.E. Crawford, P.K. Jackson, R.T. Bron-
son, and R.C. Mulligan. 1991. Neonatal lethality and lym-
phopenia in mice with a homozygous disruption of the c-abl
proto-oncogene. Cell. 65:1153–1163.
32. Hardin, J.D., S. Boast, M. Mendelsohn, K. de los Santos, and
S.P. Goff. 1996. Transgenes encoding both type I and type
IV c-abl proteins rescue the lethality of c-abl mutant mice.
Oncogene. 12:2669–2677.
33. Higgins, R.D., K. Yu, R.J. Sanders, B.N. Nandgaonkar, T.
Rotschild, and D.B. Rifkin. 1999. Diltiazem reduces retinal
neovascularization in a mouse model of oxygen induced ret-
inopathy. Curr. Eye Res. 18:20–27.
34. D’Amato, R., E. Wesoloski, and L.E. Smith. 1993. Micro-
scopic visualization of the retina by angiography with high
molecular-weight fluorescein-labeled dextrans in the mouse.
Microvasc. Res. 46:135–142.
35. Kenyon, B.M., E.E. Voest, C.C. Chen, E. Flynn, J. Folk-
man, and R.J. D’Amato. 1996. A model of angiogenesis in
the mouse cornea. Invest. Ophthalmol. Vis. Sci. 37:1625–1632.
36. Chan, T.S., C.X. Lin, W.Y. Chan, S.S. Chung, and S.K.
Chung. 1995. Mouse preproendothelin-1 gene. cDNA clon-
ing, sequence analysis and determination of sites of expression
during embryonic development. Eur. J. Biochem. 234:819–
826.
37. Breier, G., U. Albrecht, S. Sterrer, and W. Risau. 1992. Ex-
pression of vascular endothelial growth factor during embry-
onic angiogenesis and endothelial cell differentiation. Devel-
opment. 114:521–532.
38. Provis, J.M., J. Leech, C.M. Diaz, P.L. Penfold, J. Stone, and
E. Keshet. 1997. Development of the human retinal vascula-
ture: cellular relations and VEGF expression. Exp. Eye Res.
65:555–568.
39. Stone, J., T. Chan-Ling, J. Pe’er, A. Itin, H. Gnessin, and E.
Keshet. 1996. Roles of vascular endothelial growth factor and
astrocyte degeneration in the genesis of retinopathy of pre-
maturity. Invest. Ophthalmol. Vis. Sci. 37:290–299.
40. Smith, L.E., W. Shen, C. Perruzzi, S. Soker, F. Kinose, X.
Xu, G. Robinson, S. Driver, J. Bischoff, B. Zhang, et al.
1999. Regulation of vascular endothelial growth factor-
dependent retinal neovascularization by insulin-like growth
factor-1 receptor. Nat. Med. 5:1390–1395.
41. Donahue, M.L., D.L. Phelps, R.H. Watkins, M.B. LoMon-
aco, and S. Horowitz. 1996. Retinal vascular endothelial
growth factor (VEGF) mRNA expression is altered in rela-
tion to neovascularization in oxygen induced retinopathy.
Curr. Eye Res. 15:175–184.
42. Aiello, L.P., J.M. Northrup, B.A. Keyt, H. Takagi, and M.A.
Iwamoto. 1995. Hypoxic regulation of vascular endothelial
growth factor in retinal cells. Arch. Ophthalmol. 113:1538–
1544.
43. Stein, I., M. Neeman, D. Shweiki, A. Itin, and E. Keshet.
1995. Stabilization of vascular endothelial growth factor
mRNA by hypoxia and hypoglycemia and coregulation with
other ischemia-induced genes. Mol. Cell. Biol. 15:5363–5368.
44. Druker, B.J., and N.B. Lydon. 2000. Lessons learned from
the development of an abl tyrosine kinase inhibitor for
chronic myelogenous leukemia. J. Clin. Invest. 105:3–7.